Aligos Therapeutics, Inc. Common Stock (ALGS) is a publicly traded Healthcare sector company. As of November 5, 2026, ALGS trades at $4.56 with a market cap of $31.35M and a P/E ratio of -0.73. ALGS moved -6.97% today. Year to date, ALGS is -45.84%; over the trailing twelve months it is -37.86%. Its 52-week range spans $3.76 to $13.69. Analyst consensus is strong buy with an average price target of $72.50. Rallies surfaces ALGS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aligos Therapeutics to present new pevifoscorvir sodium clinical data at AASLD Liver Meeting 2026: Aligos Therapeutics said five abstracts were accepted for AASLD’s The Liver Meeting 2026 in Denver, Nov. 5-9, with poster presentations scheduled for Nov. 7-8. The abstracts cover chronic hepatitis B, including immune effects and signs of sustained viral suppression, plus preclinical hepatitis B and hepatitis delta virus programs.
| Metric | Value |
|---|---|
| Price | $4.56 |
| Market Cap | $31.35M |
| P/E Ratio | -0.73 |
| EPS | $-7.41 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.69 |
| 52-Week Low | $3.76 |
| Volume | 39.78K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.74M |
| Net Income | $-75.96M |
| Gross Margin | 0.00% |
4 analysts cover ALGS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $72.50.